Mumbai: Global pharma major Lupin Limited has announced its inclusion in prestigious S&P Global Sustainability Yearbook 2025, for the second consecutive year.
Lupin has been included in the Top 10% S&P Global CSA Score – which refers to companies that rank within the top 10% of their industry, based on their Corporate Sustainability Assessment (CSA) Score for 2024.
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment (CSA) score. Lupin's S&P Global CSA score has significantly improved, from 65 to 75, in 2024. This year, 7,690 companies assessed in the 2024 CSA were considered for the 2025 Sustainability Yearbook, out of which only 780 companies across 62 industries were recognized.
Commenting on the achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin said, “Being featured in the S&P Global Sustainability Yearbook for the second consecutive year underscores our unwavering commitment to sustainability. We are at the forefront of the pharmaceutical industry in promoting sustainable business practices globally. We remain committed to advancing impactful initiatives that support a sustainable and equitable future for our patients, communities, and stakeholders worldwide.”
Read also: Lupin bags USFDA nod for Ipratropium Bromide Nasal Solution for rhinorrhea
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.